finance.yahoo.com
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
This article reports two-year data showing that mirikizumab (Omvoh) maintained clinical and endoscopic benefit for many people with moderate–severe Crohn’s disease, and that results across Phase 3 programs also support durable remission in IBD.
That’s relevant for people considering new treatment options and for clinicians following emerging biologics.
Adults with moderately to severely active Crohn’s disease or ulcerative colitis, patients who have tried biologics before, clinicians treating IBD, and researchers tracking new IBD therapies.
What To Know
A recent report summarizes long-term results for Eli Lilly’s newly FDA-approved drug Omvoh (mirikizumab-mrkz) in Crohn’s disease from the VIVID open-label extension studies and earlier Phase 3 trials.
The article reports that many patients stayed on continuous treatment for two years and that high percentages of those in clinical or endoscopic remission at one year maintained those outcomes at two years.
It also notes that some patients not in remission at one year improved during the second year, and that the long-term safety profile was consistent with prior data.
The piece references prior Phase 3 comparisons versus placebo and ustekinumab (Stelara) and summarizes that mirikizumab showed sustained remission across Crohn’s disease and ulcerative colitis trials. It does not provide detailed trial methods, full data tables, or independent expert commentary.
If you want the original source, read the full Yahoo Finance article or the underlying Lilly trial reports and peer-reviewed publications for complete efficacy and safety details.
This is a news summary of company-reported clinical trial results and FDA approval; it references Phase 3 trials and open-label extension data but does not include full study protocols, peer-reviewed publications, or detailed safety event tables. It does not itself constitute medical advice or change recommended care.
